Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability

In this narrative review, the authors examine how oestrogen and progesterone might influence psychedelic pharmacokinetics, serotonergic signalling, subjective effects and tolerability. Female sex hormones could influence how women respond to psychedelics, including the intensity of their effects, their tolerability and potentially their therapeutic outcomes. However, the proposed hormone–psychedelic interactions are supported mainly by indirect evidence, not by clinical trials demonstrating that psychedelic efficacy varies across the menstrual cycle or stages of menopause.

Hormones may influence psychedelic exposure and duration - The authors examine how oestrogen and progesterone might affect the pharmacokinetics of orally administered psychedelics, including LSD and psilocybin.

Oestrogen and progesterone may influence serotonin 5-HT2A receptor signalling - Classic psychedelics such as LSD and psilocybin act primarily through agonism of the serotonin 5-HT2A receptor. Activation of this receptor is closely associated with acute psychedelic effects and is implicated in downstream neuroplastic processes that may contribute to therapeutic effects.

The authors review evidence from platelet receptor-binding studies and human PET/SPECT neuroimaging suggesting that hormonal status can influence 5-HT2A receptor availability.

Hormonal transitions may be relevant to women's mental health treatment - The authors explore several clinical contexts in which hormonal changes and psychiatric symptoms overlap. Their argument is that these may be important populations for future psychedelic research, not that psychedelic treatments have already been shown to work specifically for hormone-related disorders. This includes Menstrual-cycle-related mood symptoms and PMDD, Postpartum depression, Depression, anxiety and trauma-related disorders and Perimenopause and Menopause.

Hormonal contraception and hormone therapy could also matter - The review extends its discussion beyond naturally cycling women to those using exogenous hormones.

Combined hormonal contraceptives can suppress ovulation and alter endogenous hormone patterns. Menopausal hormone therapy changes the hormonal environment in ways that depend on the formulation, dose and route of administration. Gender-affirming hormone therapy is another understudied context.

The authors suggest these differences could influence psychedelic metabolism and serotonergic signalling. However, there are insufficient direct interaction studies to determine whether contraceptives or hormone therapy change the clinical efficacy, safety or optimal dose of LSD or psilocybin.

Abstract

Women experience a disproportionate burden of affective and stress-related disorders, with symptom variability shaped by endocrine transitions across the menstrual cycle, pregnancy, postpartum, and menopause. Although psychedelic-assisted therapies are increasingly investigated for these conditions, hormonal state represents a largely unaccounted determinant of variability in exposure, response, and tolerability. This narrative review synthesizes clinical, preclinical, and neuroimaging literature to examine how estradiol and progesterone modulate psychedelic pharmacokinetics, pharmacodynamics, and large-scale brain network dynamics implicated in psychiatric disorders. At the pharmacokinetic level, sex hormones influence gastrointestinal physiology (including gastric pH and transit time), tissue distribution via body composition and fluid balance, and hepatic metabolism through modulation of CYP450 enzymes, particularly CYP3A4 and CYP2D6, which are key pathways for LSD and psilocin biotransformation. Renal elimination plays a comparatively minor role.

These processes may collectively alter onset, peak concentration, and systemic exposure across hormonal states, although direct human data for psychedelics remain absent. At the pharmacodynamic level, estradiol and progesterone regulate serotonergic signaling, including dynamic modulation of 5-HT2A receptor density and binding across the menstrual cycle and reproductive lifespan. Platelet, PET, and SPECT studies indicate higher 5-HT2A availability in low-progesterone states and reduced availability in progesterone-dominant or hypoestrogenic states.

Beyond 5-HT2A, psychedelics engage broader serotonergic, glutamatergic, and GABAergic systems that converge on prefrontal-limbic, default mode, and salience networks, circuits that are also dysregulated across depression, anxiety, and trauma-related disorders. Hormonal fluctuations may further influence subjective intensity and tolerability, with potential sensitivity peaks in the early-mid follicular and early luteal phases, although direct evidence remains limited. Together, these findings suggest sex hormones as a mechanistically plausible, clinically relevant but under-characterized source of variability in psychedelic treatment response.

Kuypers, K.P.C., Mason, N.L., Carlier, A., Totomanova, I. and Haijen-Bongers, E.C.H.M. (2026). Psychedelics and women’s mental health: the effects of female sex hormones on psychedelics’ efficacy and tolerability. Molecular Psychiatry. Published online 4 August 2026. Read Paper

For more psychedelic news and research, visit the psychedelic health professional network homepage.